NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lexeo Therapeutics, Inc. (LXEO) Stock Analysis

Lexeo Therapeutics, Inc. (LXEO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LXEO

$3.00

−$0.02 (−0.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LXEO with… →

LXEO Key Statistics

As of Oct 21, 2026
Trading
Open
$3.03
Previous Close
$3.02
Day's Range
2.97–3.09
52-Week Range
2.55–10.99
Volume
1.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.64
Valuation
Market Cap
$246.26M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.02
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$99.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
82.09M
1-Year Return
−68.75%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LXEO closed at $3.00, −68.75% over 1 year.

Lexeo Therapeutics, Inc. (LXEO) has a market capitalization of $246.26M.

In fiscal 2025, LXEO reported revenue of $0.00.

LXEO Stock Return by Calendar Year

Lexeo Therapeutics, Inc. (LXEO) return since Nov 2023: what $10,000 became

1 year
$10,000 $3,125
−68.75%
3 years
$10,000 $2,985
−70.15%

If you had invested $10,000 in Lexeo Therapeutics, Inc. (LXEO) at the close on November 3, 2023, the earliest close on record here, it would have been worth $2,985 at the close on October 21, 2026: −70.15% in total, −33.17% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.79%
2025+50.91%
2024−50.97%
2023 (partial year)+33.53%

As of October 21, 2026.

LXEO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$99.96M—
2024$0.00−$98.33M—
2023$0.00−$66.39M—
2022$654.00K−$59.28M−9,063.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$109.26M−$99.96M—
2024$0.00—−$105.77M−$98.33M—
2023$0.00—−$68.51M−$66.39M—
2022$654.00K—−$60.51M−$59.28M−9,063.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Lexeo Therapeutics, Inc. (LXEO) at $246.26M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 63.

Over the past 52 weeks the price has ranged from $2.55 to $10.99. LXEO last closed at $3.00 on October 21, 2026. That is −$0.02 (−0.66%) against the previous close. The latest close sits 17.65% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $99.96M. Earnings per share on a trailing basis come to −1.02.

Across the 4 fiscal years on file, revenue moves from $654.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −68.75%. Across 3 years the annualized return works out at −33.17%. Beta against the wider market is reported at 1.64. Annualized volatility over the trailing 3 years is 97.4%.

Growth & Income

The record shows no dividend for LXEO.

So far in 2026 the total return is −69.79%. The strongest complete calendar year on file is 2025 at +50.91%; the weakest is 2024 at −50.97%.

Peer Comparison

Lexeo Therapeutics, Inc. (LXEO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lexeo Therapeutics, Inc. LXEO $246.26M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lexeo Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Visit website →